Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-906 with Gemcitabine and Erlotinib in Metastatic Pancreatic Cancer
NCT01600807Phase 2Withdrawn
- Sponsor
- Dana-Farber Cancer Institute
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linsitinib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Dana-Farber Cancer Institute. Status: withdrawn.
02
Drugs
linsitinib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01600807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01600807.